


Bioretec™

Financial Statements Bulletin
January–December 2025

Webcast
February 13, 2026



DESIGN
FROM
FINLAND®

Today's speakers



**Sarah van Hellenberg
Hubar-Fisher**

CEO



Tuukka Paavola


CFO



2025: Rebuilding for Commercial Growth

Key transitions in preparation for the next phase of growth

- CEO & CFO transition
- 5 Management Team member changes
- New U.S. Distributor Operating Model
- Go-to-Market strategy and operations adjustments
- Organizational performance enhancements
- Updated financial targets '26-'28



2025 U.S. milestones

Accelerating Growth through Regulatory Wins, Partnerships, and Execution



Regulatory & Market Access

FDA

Breakthrough

- ✓ **FDA Breakthrough Device Designation** granted for RemeOs DrillPin– **our 3rd– the first and only** absorbable implant company globally to achieve this recognition
- ✓ **CMS Transitional Pass-Through** granted for RemeOs Screw LAG Solid
- ✓ **17 VAC approvals** secured from leading clinics and institutions
- ✓ Pediatric channel developed with **OrthoPediatrics**; near-term quotas established
- ✓ Launched Training and Education and Surgeon led webinars

TPT

Payment

17

VAC Approvals




Execution & Growth

60%

Q/Q Growth

KOLs

Signed Q4 '25



- ✓ **60% Average Q/Q Growth** achieved in US direct sales (2025)
- ✓ New KOLs signed in Q4 2025 driving **early adoption & volume**
- ✓ Sales quotas deployed and actively managed across **distributor network**
- ✓ **Data-driven sales execution** using targeted analytics across RemeOs and Activa
- ✓ **Over 20 active distributor partners** in
 - Alabama, Arizona, California, Florida, Illinois, Indiana, Louisiana, Maine, Massachusetts, Michigan, New Hampshire, New Jersey, Ohio, Pennsylvania, Tennessee, Texas & Utah

Note: 1) Pass-through-payment is a US reimbursement pathway used to compensate hospitals and surgeons for the usage of innovative medical technologies not yet fully covered by standard Medicare rates; 2) Key Opinion Leader; 3) Value Analysis Committee.

2025 OUS milestones

Strategic expansion and diversification in key OUS markets


Current Footprint & New Partners

- ✓ Distributor changes completed YE 2025: **Joint Operations Ltd** appointed in UK & Ireland; **Joint Operations GmbH** in Germany & Austria.
- + New distribution partners onboarded by February in **Switzerland, China, and Turkey.**
- 📅 **3-year ('26-'28)** minimum quota volumes agreed across all new distributor agreements for the strategic period.

Strategic Initiatives

- 🎯 **China Diversification:** RemeOs™ introduction planned for Q1
- 🔍 **EU Focus:** Targeting hybrid payor, high value-recognition markets (e.g., Spain).
- 🌐 **ROW preparation:** Canada, UAE and LATAM market targeting and planning underway
- 📊 **Evidence Generation:** RemeOs™ Real World Evidence data generation strategy strictly tied to sales execution.

✓ **January 2025:** CE mark approval for the RemeOs™ Trauma Screw portfolio



Financials 2025

| EUR 1,000 unless otherwise indicated | 1-12/2025 | 1-12/2024 | Change, % |
|--------------------------------------|---------------|-----------|-----------|
| Net sales | 3,522 | 4,544 | -22.5% |
| Sales margin | 65.7% | 70.9% | |
| EBITDA | -8,476 | -4,053 | |
| Profit / loss for the period | -9,483 | -4,614 | |
| Cash and cash equivalents | 4,126 | 6,289 | -34.4% |
| Number of personnel | 60 | 47 | 27.7% |

Financial results reflect absorbing significant changes to leadership and operating model



Strategic Priorities & Financial Targets for 2026–2028



Industry Leading Innovation

Demonstrate industry leading innovation, clinical evidence generation, and **commercial scale** by progressing a strong R&D pipeline and introducing at least **one new product or indication every 12–18 months**, reflected by sustained R&D investments.



World Class Clinical and Economic Evidence Generation

Build strong market presence and solidify our commercial position in the U.S. through **direct distribution channels**, targeted Key Opinion Leader engagement strategies, and high-impact training and education.



Global Excellence in Commercialization Generation

Upgrade our OUS commercial strategy through updated distribution partner selections with rigorous and clear commercial targets and a focused effort on **RemeOs™ launches in high value markets**. Establish RemeOs as the leading **metal alloy absorbable solution** in the orthopedic implant market **globally**.

Financial Targets

- Reach **net sales exceeding EUR 10 million** by the end of the year 2028
- Maintain an **average sales margin exceeding 70%** during the strategy period

The financial targets are dependent on the necessary capital infusions required to grow in key markets like the U.S. and currently do not reflect the opportunity for acceleration through key partnerships.


Recognized Leadership in Driving the Shift to Absorbables

Bioretec will lead the charge on bioabsorbable implant growth globally

Global Bioabsorbable Orthopedic Implants Market

Market Size in USD Billion

CAGR : 10.10%



Forecast Period

2026 –2033



Market Size (Base Year)

USD 1.86 Billion



Market Size (Forecast Year)

USD 4.02 Billion



CAGR

10.10 %



Major Markets Players

- Bioretec Ltd (Finland)
- Arthrex Inc. (U.S.)
- Stryker (U.S.)
- Zimmer Biomet. (U.S.)
- Smith & Nephew (U.K.)

Near Term Product Launches: Path to Growth

Activa™ Headless

🕒 FDA 510(k) Pending



Sizes: 3.5 – 4.5 mm

Length: 20–90 mm

TAM: ~\$0.5B

Target: Trauma

RemeOs™ FT Screw

✅ FDA 510(k) Path



Sizes: 3.5 – 4.0 mm

Length: 24 – 50 mm

TAM: ~\$1.4B

Target: Trauma

BREAKTHROUGH DEVICE

RemeOs™ DrillPin

🔪 Trials Enrolling



⚡ Market Disruption

- Self-drilling (No K-wire)
- 850K Hammertoe Surgeries
- Eliminates pin tract infections

BREAKTHROUGH DEVICE

3 Near Term Approvals position Bioretec for Market Leadership

Product Pipeline — Estimated Launch Cadence

Each major product launch adds €3–5M annual revenue potential at scale

Mg alloy

Hybrid

Short-Term

Mid-Term

Long-Term

RemeOs™ FT Headless 2026

~\$0.7B TAM

BREAKTHROUGH DEVICE

Fully threaded headless compression screw targeting small bone fixation.



Differentiated Trauma

~\$3.0B TAM

ESIN nails, specialty screws, staples, and anchors leveraging absorbable technology.



Spine Portfolio

~\$3.0B TAM

BREAKTHROUGH DEVICE

SI Joint Screw and Interbody Cages utilizing osteopromotive benefits.



RemeOs™ DrillPin 2026

~\$2.1B TAM

BREAKTHROUGH DEVICE

Game-changer: Self-drilling pin targeting **850K+ hammertoe surgeries** annually.



RemeOs™ Upper Extremities

~\$1.4B TAM

Expansion of indication labels to include wrist, elbow, and shoulder applications.



IM-Nails

~\$2.6B TAM

Large bone intramedullary nails for tibia and femur fractures.™



Activa™ Headless 2026

~\$0.7B TAM

Polymer headless screw expanding pediatric and hand/wrist indications.



Plates

~\$4.0B TAM

Comprehensive plating systems replacing permanent hardware.



In house development

In-house development + partners

In-house development + partners + licencing

Market Momentum:

Leading Surgeons are Ready for the Absorbable Shift



Prof. Dr. Christopher DiGiovanni

FACFAS, double Board Certified Foot and Ankle surgeon,

*"Absorbable fixation is positioned to become an increasingly important part of foot and ankle surgery. My engagement with the **Bioretec Scientific Advisor Board** reflects an interest in supporting the careful scientific research, development, and **advancement of these technologies.**"*



Dr. Robert Leland

FACFAS, Board Certified Foot & Ankle Surgeon

*"**Bioretec implants have delivered** predictable healing of fractures, fusions and osteotomies **without the need for hardware removal.** I'm excited for the future of bioabsorbable implants in general and Bioretec's implants specifically as this technology becomes more integrated into patient care."*



Dr. Gary Stewart

Board Certified Foot & Ankle Surgeon, FACFAS

*"I have found **RemeOs** to provide **excellent initial fixation as well as long-term reduction** and fixation with the added benefit of not necessitating hardware removal"*



Dr. James Cottom

DPM, FACFAS


*"**This technology is amazing**, and I feel it will be **a major disruptor in the orthopedic implant market.** I look forward to treating my patients with a metal free option going forward!"*



Bioretec™

Questions & Answers

**Two Absorbable
Technologies, One Goal —
Healing Beyond Absorption**



**DESIGN
FROM
FINLAND**

Pathways to value creation



Activa™



- Proprietary manufacturing process extends protection beyond current patent life
- **Clear repeat market demand and comparable valuation benchmarking with Ossio in the US**
- US Upper Extremities remains untapped in current resourcing model, ready now



RemeOs™ Trauma



- Near term trauma portfolio expected in **<18 months**
- **DrillIPin gamechanger:**

Self-drilling simplicity: No pre-drill, no extra hardware, fewer steps than other absorbables, real versatility- indication base expands to where fiber-based nails are restricted. TAP program invite.
- Stronger than bone when it matters: Flexural strength 3–4× cortical bone, then gradual load transfer back to the healing bone as it resorbs



RemeOs™ Spine



- **Pre-commercial partnership** strategy
- SI screw serving as strategic **door opener expected to be game changing for spine procedures**
- Cage already **Breakthrough Designated**
- Preclinical readouts expected within strategic period




3 distinct product families to drive value, 3 different IP families

\$14B+ market potential with strong absorbables CAGR

Addressable market for full product line-up >\$14B...

... with strong absorbables outlook (CAGR 10%+)

Addressable market, 2024 estimate




Trauma Screw market alone to reach ~\$2.5B by 2033

Activa is positioned to capture share in Ped. Trauma/extremities, sports med

RemeOs is positioned to take share from full trauma/extremities/sports med in the near term + spine

Bioretec™

Two Absorbable
Technologies, One Goal —
Healing Beyond Absorption



DESIGN
FROM
FINLAND